The James Buchanan Brady Urological Institute at Johns Hopkins Medicine has a newly endowed division, called the Robert Altman Division of Minimally Invasive Surgery, following a $10 million gift from the Robert and Lynda Altman Family Foundation. The gift supports ongoing research, education and care to support the world-renowned center, which provides less-invasive surgical care to patients of all ages presenting with a range of urological conditions.

A study by the University of Barcelona has discovered why the two main types of lung cancer — adenocarcinoma of the lung and squamous cell carcinoma — respond differently to anti-angiogenic therapy, that is, drugs that block the formation of new blood vessels that tumours need in order to grow. The results, published in the journal CCell Death & Disease, show that these differences largely depend on the environment surrounding the tumours, particularly on some very abundant benign cells called fibroblasts. This finding opens the door to the development of more personalized therapies, tailored to the specific characteristics of each tumour’s microenvironment.

University of Maryland School of Medicine (UMSOM) Researchers have identified a target that may improve the response of CAR T-cell therapy, a treatment for patients with recurrent or difficult to treat blood cancers.

In a recent study published in Signal Transduction and Targeted Therapy, scientists found increased survival and tumor-fighting activity in lab and animal models when they blocked a specific protein in the modified cells.

BUFFALO, NY – June 15, 2026 – A new research paper was published in Volume 17 of Oncotarget on June 5, 2026, titled “A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence.”

Patients with relapsed multiple myeloma lived significantly longer without disease progression and showed early survival gains in a global phase 3 trial of a talquetamab-based immunotherapy combo, offering new hope for improved treatment outcomes.

Los Angeles, CA – June 15, 2026 – Researchers from the Terasaki Institute for Biomedical Innovation  together with key pioneers in glioma biology, neuro-oncology, and stem cell biology, have published a comprehensive review in Society for Neuro-Oncology’s journal Neuro-Oncology outlining the evolving landscape of glioma organoid technologies and proposing a foundational classification framework to guide translational brain tumor research.